Thrombolytic and Pharmacokinetic Properties of Human Tissue-Type Plasminogen Activator Variants, Obtained by Deletion and/or Duplication of Structural/Functional Domains, in a Hamster Pulmonary Embolism Model

D Collen; H R Lijnen; I Vanlinthout; L Kieckens; L Nelles; J M Stassen

doi:10.1055/s-0038-1647479

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 1991; 65(02): 174-180
DOI: 10.1055/s-0038-1647479

Original Article

Schattauer GmbH Stuttgart

Thrombolytic and Pharmacokinetic Properties of Human Tissue-Type Plasminogen Activator Variants, Obtained by Deletion and/or Duplication of Structural/Functional Domains, in a Hamster Pulmonary Embolism Model

Authors

D Collen

The Center for Thrombosis and Vascular Research, University of Leuven, Belgium
H R Lijnen

The Center for Thrombosis and Vascular Research, University of Leuven, Belgium
I Vanlinthout

The Center for Thrombosis and Vascular Research, University of Leuven, Belgium
L Kieckens

The Center for Thrombosis and Vascular Research, University of Leuven, Belgium
L Nelles

The Center for Thrombosis and Vascular Research, University of Leuven, Belgium
J M Stassen

The Center for Thrombosis and Vascular Research, University of Leuven, Belgium

Abstract

PDF Download

Summary

A pulmonary embolism model in hamsters was used for the quantitative evaluation of the thrombolytic and pharmacokinetic properties of variants of tissue-type plasminogen activator (t-PA). A 25 μi ¹²⁵I-fibrin labeled human plasma clot was made in vitro and injected into the jugular vein of heparinized hamsters. The extent of thrombolysis within 90 min was determined as the difference between the radioactivity injected in the jugular vein and that recovered in the heart and lungs.

Recombinant t-PA (home-made rt-PA or Activase^®) infused intravenously over 60 min caused dose-dependent progressive thrombolysis. The results of thrombolytic potency (clot lysis in percent versus dose administered in mg/kg) and of specific thrombolytic activity (clot lysis in percent versus steady state plasma level in μg/ml) were fitted with an exponentially transformed sigmoidal function y = 100 c/(1+e^{−a(e^x−e^b)}) and the maximal percent lysis (c), the dose or plasma level at which maximal rate of lysis is achieved (b) and the maximal rate of lysis (z = ¼ ac .e^b) were determined. With rt-PA, these parameters were c = 72 ± 6% (mean ± SEM), b = 0.19 ± 0.08 mg/kg, z = 68 ± 25% lysis per mg/kg, with corresponding values of 87 ± 5%, 0.07 ± 0.03 mg/kg and 150 ± 38% lysis per mg/kg for Activase^® (p = NS). Deletion of the finger and growth factor domains in rt-PA ( rt-PA-ΔFE) was not associated with marked alteration of the thrombolytic potency (c = 90 ± 30%, b = 0.34 ± 0.35 mg/kg, and z = 54 ± 14% per mg/kg), but was associated with a significant reduction of the specific thrombolytic activity. Substitution of the kringle 1 domain by a second copy of the kringle 2 domain in rt-PA and in rt-PA-ΔFE did not significantly alter the thrombolytic potency as characterized by a simultaneous decrease of the b value and an increase of the z value (b = 0.07 ± 0.03 mg/kg and z = 210 ± 70% per mg/kg for rt-PA-ΔK₁∇K₂ and b = 0.13 ± 0.02 mg/kg and z = 210 ± 29% per mg/kg for rt-PA-ΔFEK₁∇K2). Deletion of either the finger or the growth factor domain in rt-PA-ΔK₁∇K₂ also did not significantly alter the thrombolytic potency (b = 0.08 ± 0.008 mg/kg and z = 320 ± 33% per mg/kg for rt-PA-ΔEK₁∇K₂ and b = 0.05 ± 0.01 mg/kg and z = 270 ± 48% per mg/kg for rt-PA-ΔFK₁∇K₂). Likewise, none of the variants had a higher specific thrombolytic activity than wild-type rt-PA. Plasma clearance rates were reduced 10- to 20-fold for the rt-PA mutants lacking the FE domains, and 3- to 5-fold for rt-PA-ΔK₁∇K₂.

PDF (1373 kb)

References

REFERENCES
1 Collen D, Lijnen HR, Todd PA, Goa KL. Tissue-type plasminogen activator. A review of its pharmacology and therapeutic use as a thrombolytic agent. Drugs 1989; 38: 346-388
2 Pennica D, Holmes WE, Kohr WJ, Harkins RN, Vehar GA, Ward CA, Bennett WF, Yelverton E, Seeburg PH, Heyneker HL, Goeddel DV, Collen D. Cloning and expression of human tissue-type plasminogen activator cDNA in E. coli. Nature 1983; 301: 214-221
3 Ny T, Elgh F, Lund B. The structure of the human tissue-type plasminogen activator gene: correlation of intron and exon structures to functional and structural domains. Proc Natl Acad Sci USA 1984; 81: 5355-5359
4 Hoylaerts M, Rijken DC, Lijnen HR, Collen D. Kinetics of the activation of plasminogen by human tissue plasminogen activator. Role of fibrin. J Biol Chem 1982; 257: 2912-2919
5 van Zonneveld AJ, Veerman H, Pannekoe H. Autonomous functions of structural domains on human tissue-type plasminogen activator. Proc Natl Acad Sci USA 1986; 83: 4670-4674
6 Collen D, Stassen JM, Larsen G. Pharmacokinetics and thrombolytic properties of deletion mutants of human tissue-type plasminogen activator in rabbits. Blood 1988; 71: 216-219
7 Browne MJ, Carey JE, Chapman CG, Tyrrell AW, Entwisle C, Lawrence GM, Reavy B, Dodd IS, Esmail A, Robinson JH. A tissue-type plasminogen activator mutant with prolonged clearance in vivo. Effect of removal of the growth factor domain. J Biol Chem 1988; 263: 1599-1602
8 Kalyan NK, Lee SG, Wilhelm J, Fu KP, Hum WT, Rappaport R, Hartzell RW, Urbano C, Hung PP. Structure-function analysis with tissue-type plasminogen activator. Effect of deletion of NH 2-terminal domains on its biochemical and biological properties. J Biol Chem 1988; 263: 3971-3978
9 Lijnen HR, Nelles L, Van Hoef B, De Cock F, Collen D. Biochemical and functional characterization of human tissue-type plasminogen activator variants obtained by deletion and/or duplication of structural/functional domains. J Biol Chem 1990; 265: 5677-5683
10 Stassen JM, Vanlinthout I, Lijnen HR, Collen D. A hamster pulmonary embolism model for the evaluation of the thrombolytic and pharmacokinetic properties of thrombolytic agents. Fibrinolysis 1990; 4 (Suppl. 02) 15-21
11 Tate KM, Higgins DL, Holmes WE, Winkler ME, Heyneker HL, Vehar GA. Functional role of proteolytic cleavage at Arginine-275 of human tissue plasminogen activator as assessed by site-directed mutagenesis. Biochemistry 1987; 26: 338-343
12 Clauss A. Gerinnungsphysiologische Schnellmethode zur Bestim-mung des Fibrinogens. Acta Haematol 1957; 17: 237-246
13 Vermylen J, De Vreker R, Verstraete M. A rapid enzymatic method for assay of fibrinogen: the fibrin polymerization test (F. P. T.). Clin Chim Acta 1963; 8: 418-424
14 Edy J, Collen D, Verstraete M. Quantitation of the plasma protease inhibitor antiplasmin with the chromogenic substrate S-2251. In: Progress in Chemical Fibrinolysis and Thrombolysis, Vol. 3 Davidson JF, Rowan RM, Samama MM, Desnoyers PC. (eds) Raven Press; New York: 1978: 315-322
15 Holvoet P, Cleemput H, Collen D. Assay of human tissue-type plasminogen activator (t-PA) with an enzyme-linked immunosorbent assay (ELISA) based on three murine monoclonal anticlonal antibodies to t-PA. Thromb Haemostas 1985; 54: 684-687
16 Gibaldi M, Perrier D. Pharmacokinetics. Marcel Dekker New York: 1983: 45-111
17 Cambier P, Van de WerfF, Larsen GR, Collen D. Pharmacokinetics and thrombolytic properties of a nonglycosylated mutant of human tissue-type plasminogen activator, lacking the finger and growth factor domains, in dogs with copper coil-induced coronary thrombosis. J Cardiovasc Pharmacol 1988; 11: 468-472
18 Kominger C, Stassen JM, Collen D. Turnover of human extrinsic (tissue-type) plasminogen activator in rabbits. Thromb Haemostas 1981; 46: 658-661
19 Fuchs HE, Berger H, Pizzo SV. Catabolism of human tissue plasminogen activator in mice. Blood 1985; 65: 539-544
20 Rijken DC, Emeis JJ. Clearance of the heavy and light polypeptide chains of human tissue-type plasminogen activator in rats. Biochem J 1986; 238: 643-646
21 Flameng W, Van de Werf F, Vanhaecke J, Verstraete M, Collen D. Coronary thrombolysis and infarct size reduction after intravenous infusion of recombinant tissue-type plasminogen activator in nonhuman primates. J Clin Invest 1985; 75: 84-90
22 Verstraete M BounameauxH, De Cock F, Van de WerfF, Collen DS. Pharmacokinetics and systematic fibrinogenolytic effects of recombinant human tissue-type plasminogen activator (rt-PA) in humans. J Pharmacol Exp Therap 1985; 235: 506-512
23 Verstraete M, Su CAPF, Tanswell P, Feuerer W, Collen D. Pharmacokinetics and effects on fibrinolytic and coagulation parameters of two doses of recombinant tissue-type plasminogen activator in healthy volunteers. Thromb Haemostas 1986; 56: 1-5
24 Garabedian HD, Gold HK, Leinbach RC, Johns JA, Yasuda T, Kanke M, Collen D. Comparative properties of two clinical preparations of recombinant human tissue-type plasminogen activator in patients with acute myocardial infarction. J Am Coll Cardiol 1987; 9: 599-607
25 Larsen GR, Henson K, Blue Y. Variants of human tissue-type plasminogen activator. Fibrin binding, fibrinolytic, and fibrinogenolytic characterization of genetic variants lacking the fibronectin fingerlike and/or the epidermal growth factor domains. J Biol Chem 1988; 263: 1023-1029
26 Verheijen JH, Caspers MPM, Chang GTG, De Munk GAW, Pouwels PH, Enger-Valk BE. Involvement of finger domain and kringle 2 domain of tissue-type plasminogen activator in fibrin binding and stimulation of activity by fibrin. EMBO J 1986; 5: 3525-3530